Clinical Research Directory

Inclusion Criteria: * Confirmed histologic diagnosis of c-Myc rearranged high-grade B-cell lymphoma * Relapse or refractory disease after at least one previous line of therapy * Measurable disease as defined by 2014 Lugano classification * ECOG performance status of 0-2 * Acceptable coagulation parameters Exclusion Criteria: * Allogeneic transplant within 3 months * Autologous transplant without resolution of post-transplant cytopenias * Known CNS involvement * Average QT/QTc interval duration \> 450 msec * Inadequate marrow, hepatic or renal function * Unresolved Grade 2 or greater toxicities from prior anticancer therapy * Radiotherapy within prior 4 weeks * Requires systemic immunosuppressive therapy * Positive for Hepatis B or Hepatis C * Seropositive for HIV